Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

77.85 +0.77 (+1.00%)
Streaming Delayed Price Updated: 1:23 PM EST, Dec 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗
Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027. 
Via Benzinga
News headline image
Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug ↗
Ionis' olezarsen cut triglycerides by up to 72% and reduced acute pancreatitis events by 85% in Phase 3 studies of severe hypertriglyceridemia. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease ↗
Via Stocktwits
News headline image
Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗
The company remains confident in its other gene-editing product, which would treat a swelling disorder. 
Via Investor's Business Daily
Topics Death
News headline image
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗
Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam... 
Via Benzinga
News headline image
Ionis (IONS) Q3 2025 Earnings Call Transcript ↗
Ionis (IONS) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗
The company easily beat third-quarter expectations and issued guidance that widely topped forecasts. 
Via Investor's Business Daily
News headline image
Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗
Via The Motley Fool
News headline image
31 Analysts Assess Ionis Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows Strong Growth Momentum and Technical Strength ↗
IONIS Pharmaceuticals stock shows strong technical and fundamental momentum, meeting strict trend-following criteria with surging earnings and revenue growth. 
Via Chartmill
News headline image
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
News headline image
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike ↗
The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs. 
Via Investor's Business Daily
News headline image
This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Ionis Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial ↗
Ionis reports positive pivotal study results for zilganersen in Alexander disease, showing gait speed benefits and strong safety data. 
Via Benzinga
News headline image
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status ↗
FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements. 
Via Benzinga
News headline image
Here are the top movers in Tuesday's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies ↗
In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction ↗
Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events. 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch. ↗
Ionis Pharmaceuticals scored the "bull case" Tuesday after its experimental treatment for high triglycerides beat the placebo. 
Via Investor's Business Daily
News headline image
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Presents a High-Probability Technical Breakout Setup ↗
IONIS Pharmaceuticals (IONS) shows strong technicals with a high setup rating, signaling a potential breakout from its current consolidation pattern. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.